Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: james who wrote (2921)	11/21/1997 1:41:00 AM
From: Peter Singleton	Read Replies (2) \| Respond to of 6136

re: cross resistance and Viracept The following quote was in Steven Deeks MD's ICAAC summary posted on UCSF's website hivinsite.ucsf.edu. BTW, Dr Deeks was one of the researchers that presented the study at ICAAC on real-world combination therapy failure rates that got such widespread and mis-understood press. He's definitely a heavy hitter in AIDS medical practice. "Conclusion: This encouraging data suggests that salvage therapy after failing nelfinavir may be possible. This is in contrast to evolving experience in patients failing indinavir and ritonavir therapy. If these trends persist, using nelfinavir as a first line protease inhibitor, and saving other drugs for salvage, may prove to be an appropriate therapeutic strategy." Peter